ABSTRACTa2-Adrenergic receptors comprise a heterogeneous population based on pharmacologic and molecular evidence. We have isolated a cDNA clone (pRNGa2) encoding a rat a2-adrenergic receptor. A rat kidney cDNA library was screened with an oligonucleotide complementary to a highly conserved region found in all biogenic amine receptors described to date. The deduced amino acid sequence displays many features of guanyl nucleotide-binding protein-coupled receptors except it does not have a consensus N-linked glycosylation site near the amino terminus. Membranes prepared from COS cells transfected with pRNGa2 DNA display high affinity and saturable binding to [3H]rauwolscine (Kd = 2 nM).Competition curve data analysis shows that RNGa2 protein binds to a variety of adrenergic drugs with the following rank order of potency: yohimbine 2 chlorpromazine > prazosin 2 clonidine > norepinephrine 2 oxymetazoline. RNGa2 RNA accumulates in both rat kidney and neonatal rat lung (predominant species is 4000 nucleotides). When a cysteine residue (a2-C10), isolated from a human genomic library, encodes an a2A subtype (3), whereas a second clone (a2-C4), isolated from a human kidney cDNA library, encodes a subtype with some of the properties expected of Bylund's a2B subtype (4). For example, the a2-C4 protein has a greater affinity for prazosin than oxymetazoline but is glycosylated following expression of the cDNA in COS cells. Venter and colleagues (5) have further shown that the a2A-adrenergic clone is functional in that Chinese hamster ovary cells transfected with this DNA respond to a2-adrenergic agonists by inhibiting forskolin-stimulated increases in cAMP. Southern blots of human genomic DNA hybridized to a2A-adrenergic receptor DNA showed the existence of three sets of bands, and only two of these were accounted for by known (i.e., a2-C10 and a2-C4) adrenergic receptor genes (3, 4). Thus it appears that there exists a third, closely related gene in the a2-adrenergic subfamily.To obtain the full set of a2-adrenergic clones for our studies on the role of a2-adrenergic receptors in blood pressure control, we screened a rat kidney cDNA library with an oligonucleotide derived from a consensus nucleotide sequence of known biogenic amine receptors. In this report we describe a cDNA encoding a molecule with the ligand binding, tissue distribution, and structural properties expected of an a2B-adrenergic receptor. § METHODS Cloning and Sequence Analysis. Two degenerate oligonucleotides (5'-CTNGAYGTGCTGTKCTGCACSKCSTC-CATCPTGMACCTGTGCG-3' and 5'-CAGSSYGATGPCG-CACAGGT-3'; N = G, A, T, or C; Y = T or C; K = G or T; S = G or C; P = A or G; and M = A or C) were synthesized on a Biosearch 8600 syfnthesizer and purified. The 3' terminal nonamers of these oligonucleotides are complementary; labeled, double-stranded DNA was prepared by the action ofthe Klenow fragment of DNA polymerase I on the annealed oligonucleotide templates in the presence of radiolabeled (32p) deoxynucleoside triphosphates. The resulting 54-residue, 8192-fold degenerat...
In two multicenter phase III efficacy studies, blood samples were obtained to evaluate the serum concentrations of 17beta-estradiol (E2) and unconjugated estrone (E1) after administration of a percutaneous gel or transdermal patch containing estradiol. In postmenopausal women, normal laboratory E2 and E1 serum concentrations range from 10-30 pg/mL and 20-40 pg/mL, respectively. Study subjects were healthy postmenopausal women with moderate to severe hot flushes occurring at least seven times daily or 60 times per week. Study 1 was a randomized, double-blind, multicenter study of percutaneous E2 gel 1.25 or 2.5 g (0.75 and 1.5 mg E2, respectively) versus placebo gel. Study 2 was a double-blind (blinded to E2 gel dose), randomized, active-controlled, multicenter, 12-week phase 3 study of E2 gel 0.625, 1.25, or 2.5 g (0.375, 0.75, or 1.5 mg E2, respectively) versus a transdermal E2 patch delivering 0.05 mg E2 per day. Serum E2 and E1 concentrations were evaluated at baseline and at week 12 for study 1 and at baseline and weeks 4, 8, and 12 for study 2 using radioimmunoassay. Median serum concentrations of E2 after 1.25- and 2.5-g gel administration appeared to be dose-proportional throughout both studies. In study 1, the median serum concentrations of E2 at week 12 were 33.5 and 65.0 pg/mL for 1.25- and 2.5-g gel dose, respectively. The corresponding E1 values were 49.0 and 58.0 pg/mL. In study 2, both E2 and E1 concentrations were relatively stable at weeks 4, 8, and 12. E2 values at week 12 for 0.625-, 1.25-, and 2.5-g gel doses and E2 patch were 25.0, 32.0, 60.0, and 38.5 pg/mL, respectively. The corresponding E1 values were 39.0, 41.0, 62.5, and 40.0 pg/mL. Application of the 1.25-g gel dose and a transdermal patch delivering 50 microg per day of E2 resulted in comparable median E2 and E1 concentrations. However, the 0.625-g gel dose did not produce E2 levels in a range expected to be consistently therapeutic in most postmenopausal women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.